Biovie Inc. (BIVI): Cash & Equivalents
$8.98M
As of 2026-06-30
-22.7%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $8.98M | -48.8% | 2026-08-13, Balance as of period end |
| 2025-06-30 | $17.54M | -26.4% | 2026-08-13, Balance as of period end |
| 2024-06-30 | $23.84M | +22.5% | 2025-08-15, Balance as of period end |
| 2023-06-30 | $19.46M | +4.4% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $18.64M | n/a | 2023-08-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Biovie Inc. (BIVI) | 2026-06-30 | $8.98M | -48.8% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $13.16M | +52.3% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $11.85M | -0.4% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $7.56M | +24.6% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $11.52M | +45.2% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $13.20M | -43.3% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $10.80M | +980.0% |
| Cingulate Inc. (CING) | 2025-12-31 | $10.95M | -10.3% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $14.67M | -22.2% |
Compare BIVI, ACTU, CYDY, CMMB side by side · Screen every company in Pharmaceutical Preparations ↗